Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
CMPXthis companyCompass Therapeutics, Inc.	$0.78	-12.79×	4.3×	0×	-12.7×	-84.0%	0.0%	0.0%	0.0%	-33.8%	-35.3%	-5.8%	0.05×	0.32×	0×	15.02×	0.0%	3	-0.29	2	C+
CRVSCorvus Pharmaceuticals, Inc.	$10.66	-40.53×	9.93×	0×	-39.82×	-99.8%	0.0%	0.0%	0.0%	-25.0%	-69.1%	-5.4%	0.02×	0.24×	0×	6.21×	0.0%	2	32.84	2	C
FDMT4D Molecular Therapeutics, Inc.	$12.28	-3.1×	0.86×	5.1×	-2.99×	-184.8%	91.1%	-187.2%	-164.4%	-27.7%	-30.2%	-25.1%	0.04×	0.29×	0×	9.39×	0.0%	3	1.71	2	C
FULCFulcrum Therapeutics, Inc.	$3.71	-9.58×	2.05×	0×	-7.15×	-17.6%	0.0%	0.0%	0.0%	-21.5%	-23.8%	-8.4%	0.02×	2.6×	0×	27.4×	0.0%	2	10.2	3	B
GOSSGossamer Bio, Inc.	$9.86	-4.16×	-5.77×	14.62×	-5.51×	1153.6%	97.9%	-336.8%	-351.5%	138.8%	-148.7%	-24.2%	-1.65×	-1.04×	-14.86×	2.64×	0.0%	3	-35.69	2	C+
LXRXLexicon Pharmaceuticals, Inc.	$1.85	-8.21×	3.88×	8.38×	-10.76×	-701.5%	99.4%	-98.2%	-101.1%	-46.8%	-28.7%	-16.3%	0.58×	-0.67×	-5.87×	4.88×	0.0%	2	-6.05	1	D+
Peer median	—	-8.21×	2.05×	5.1×	-7.15×	-99.8%	91.1%	-98.2%	-101.1%	-25.0%	-30.2%	-16.3%	0.02×	0.24×	0×	6.21×	0.0%	2	1.71	2	—